Elixinol LLC Logo SQ Blue.png
Source: Elixinol LLC

Elixinol and KBMD Health Launch New Hemp CBD Extract

Leading Hemp-Derived CBD Brand Partners with Renowned Gastroenterologist to Create New Product

DENVER, April 18, 2019 (GLOBE NEWSWIRE) -- Elixinol, one of the most influential CBD brands in the world with nearly three decades of experience in the hemp industry, announces its latest product in partnership with Ken Brown, MD of KBMD Health, KBMD CBD Extract in Elixinol’s signature Natural and Cinnamint flavors. Created in partnership with Dr. Brown, an established physician specializing in gastroenterology, this full-spectrum product contains 900mg of CBD in a 1oz tincture, and is intended to help promote abdominal health and support relief from discomfort in those impacted by digestive issues.

Passionate about bridging the gap between natural and medical science, Dr. Brown has been utilizing Elixinol hemp CBD extract for over two years in his own gastroenterology practice to support the digestive wellness of hundreds of patients. Dr. Brown indicates that his patients typically report feeling better when consuming a daily serving size of 30mg (15mg twice per day).  

“Elixinol’s hemp CBD extracts have proven to be instrumental to my patients who have expressed discomfort caused by digestive issues,” said Dr. Brown. “Elixinol’s dedication to quality, third-party tested CBD products, as well as clean sourcing, extraction and production processes, made it an easy decision in terms of a partner for this product.”

“Elixinol is proud to partner with KBMD Health to produce this hemp CBD extract,” said Chris Husong, VP of Marketing and Communications at Elixinol. “Specialists like Dr. Brown are going to help us pave the way for the future of the quickly growing and evolving CBD industry. He’s helping those who are newer to the world of cannabinoids understand the vast potential for daily health and wellness.”

KBMD Hemp CBD Extract is available at KBMDHealth.com/product/ for a suggested retail price of $89.99 in Elixinol’s signature Natural and Cinnamint flavors.

About Elixinol
Colorado-based Elixinol, co-founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and extracting premium-quality hemp, Elixinol is one of the few CBD hemp extract brands with complete seed-to-sale control over its products. Elixinol also conducts rigorous third-party laboratory testing and quality control. Elixinol distributes hemp-derived CBD products in 40 countries globally including North and South America, throughout Europe, Asia, and the Pacific Region under its own label as well as bulk CBD and wholesale CBD. Elixinol is a wholly owned subsidiary of Elixinol Global (EXL) (elixinolglobal.com) which is publicly traded on the Australian Securities Exchange and on the U.S. OTC (ASX:EXL, OTCQX: ELLXF). More information available at Elixinol.com.

About KBMD Health
Dr. Ken Brown is a renowned physician in the gastroenterology field passionate about “bridging the gap” between medical and natural sciences. Truly believing that learning doesn’t stop once a Doctorate is achieved, Dr. Brown started a clinical research effort over a decade ago in order to uncover new and innovative approaches to health and wellness. In addition to the KBMD 900mg Natural CBD Extracts he partnered with Elixinol on, Dr. Brown created Atrantil Capsules, geared to relieve symptoms of bloating and abdominal discomfort with a natural approach using polyphenols. Dr. Brown has been featured in many top-tier publications, multiple TV platforms, and several podcasts. He has recently launched the “Gut Check Project” digital radio show and podcast where he hosts great guests to talk health, science, and more on his expertise and mission. More information available at KBMDHealth.com.

Media Contacts:
Blythe Tokar
+1 202-292-4573
elixinol@wearemultip.ly

Chris Husong
Elixinol
+1 844-804-3504 ext 420
chris@elixinol.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/98181c8d-0229-4925-8319-aecaae58d633

Attachments: